Trial Profile
An open-label, single-arm, prospective study of TACE combined with apatinib for unresectable liver metastases from colorectal cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- 06 Nov 2017 New trial record